Xspray Pharma AB (publ)

OM:XSPRAY Stock Report

Market Cap: SEK 1.2b

Xspray Pharma Management

Management criteria checks 1/4

Xspray Pharma's CEO is Per Andersson, appointed in Jan 2006, has a tenure of 19.33 years. total yearly compensation is SEK4.28M, comprised of 70.2% salary and 29.8% bonuses, including company stock and options. directly owns 0.52% of the company’s shares, worth SEK6.11M. The average tenure of the management team and the board of directors is 1.7 years and 6 years respectively.

Key information

Per Andersson

Chief executive officer

SEK 4.3m

Total compensation

CEO salary percentage70.21%
CEO tenure19.3yrs
CEO ownership0.5%
Management average tenure1.7yrs
Board average tenure6yrs

Recent management updates

Recent updates

Is Xspray Pharma (STO:XSPRAY) Weighed On By Its Debt Load?

Apr 03
Is Xspray Pharma (STO:XSPRAY) Weighed On By Its Debt Load?

We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully

Feb 25
We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

May 11
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth

Feb 01
We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Oct 26
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Jun 20
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely

Mar 19
We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely

Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?

Feb 12
Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?

Here's Why We're Watching Xspray Pharma's (STO:XSPRAY) Cash Burn Situation

Dec 04
Here's Why We're Watching Xspray Pharma's (STO:XSPRAY) Cash Burn Situation

CEO Compensation Analysis

How has Per Andersson's remuneration changed compared to Xspray Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-SEK 260m

Dec 31 2024SEK 4mSEK 3m

-SEK 286m

Sep 30 2024n/an/a

-SEK 258m

Jun 30 2024n/an/a

-SEK 215m

Mar 31 2024n/an/a

-SEK 213m

Dec 31 2023SEK 4mSEK 3m

-SEK 180m

Sep 30 2023n/an/a

-SEK 180m

Jun 30 2023n/an/a

-SEK 170m

Mar 31 2023n/an/a

-SEK 148m

Dec 31 2022SEK 4mSEK 2m

-SEK 132m

Sep 30 2022n/an/a

-SEK 128m

Jun 30 2022n/an/a

-SEK 114m

Mar 31 2022n/an/a

-SEK 102m

Dec 31 2021SEK 3mSEK 2m

-SEK 97m

Sep 30 2021n/an/a

-SEK 60m

Jun 30 2021n/an/a

-SEK 57m

Mar 31 2021n/an/a

-SEK 56m

Dec 31 2020SEK 3mSEK 2m

-SEK 52m

Sep 30 2020n/an/a

-SEK 56m

Jun 30 2020n/an/a

-SEK 55m

Mar 31 2020n/an/a

-SEK 49m

Dec 31 2019SEK 3mSEK 2m

-SEK 46m

Sep 30 2019n/an/a

-SEK 41m

Jun 30 2019n/an/a

-SEK 34m

Mar 31 2019n/an/a

-SEK 30m

Dec 31 2018SEK 2mSEK 2m

-SEK 23m

Compensation vs Market: Per's total compensation ($USD439.23K) is above average for companies of similar size in the Swedish market ($USD276.81K).

Compensation vs Earnings: Per's compensation has increased whilst the company is unprofitable.

CEO

Per Andersson (57 yo)

19.3yrs

Tenure

SEK 4,276,000

Compensation

Dr. Per Andersson Ph.D. has been the Chief Executive Officer of Xspray Pharma AB (publ) since 2006. Dr. Andersson serves as the Chief Executive Officer of Xspray Microparticles AB. Dr. Andersson joined XSp...

Leadership Team

NamePositionTenureCompensationOwnership
Per Andersson
Chief Executive Officer19.3yrsSEK 4.28m0.52%
SEK 6.1m
Mustafa Demirbüker
Co-Founder and Science Directorno datano datano data
Niklas Adenborg
Chief Financial Officerless than a yearno datano data
Linda Glimberg
Chief Operating Officerless than a yearno data0.0049%
SEK 56.7k
Charlotta Liljebris
Senior Vice President of Research & Development7.3yrsno data0.0081%
SEK 94.5k
Edward Jordan
Chief Commercial Officer1.7yrsno datano data
Anette Abrahamsson
Senior Vice President of Regulatory Affairs1.3yrsno data0.0040%
SEK 47.3k
Christer Hallgren
Senior Vice President of Intellectual Property7.3yrsno data0.081%
SEK 944.9k

1.7yrs

Average Tenure

56yo

Average Age

Experienced Management: XSPRAY's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Maris Hartmanis
Independent Director10.3yrsSEK 348.00k0.083%
SEK 976.6k
Carl-Johan Spak
Independent Director10.3yrsSEK 293.00kno data
Anders Ekblom
Chairman4yrsSEK 550.00k1.55%
SEK 18.2m
Torbjörn Koivisto
Independent Director8.3yrsSEK 273.00kno data
Christine Lind
Independent Director6yrsSEK 293.00k0.013%
SEK 148.2k
Anders Bladh
Director4yrsSEK 273.00k0%
SEK 0
Robert Molander
Independent Director3yrsSEK 238.00k0.027%
SEK 315.0k

6.0yrs

Average Tenure

66yo

Average Age

Experienced Board: XSPRAY's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/15 15:22
End of Day Share Price 2025/05/15 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xspray Pharma AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dan AkschutiPareto Securities
Filip EinarssonRedeye